TONIX is developing new treatments for CNS syndromes, including fibromyalgia and post-traumatic stress disorder.
TONIX is developing TNX-102 SL with the goal of improving the quality of life in patients suffering from fibromyalgia syndrome.
TONIX is developing TNX-102 SL with the goal of providing relief for post-traumatic stress disorder.
TONIX Pharmaceuticals Holding Corp. (TNXP)
At TONIX Pharmaceuticals, we are developing new treatments for challenging disorders of the central nervous system (CNS).
The Company’s lead program is a potential new treatment for fibromyalgia and post-traumatic stress disorder, which are chronic CNS syndromes. In each of these programs, TONIX seeks to use new doses and formulations of cyclobenzaprine in new treatment regimens. Cyclobenzaprine is the active ingredient of two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration (FDA) and are marketed by other companies.